Highlights Amgen Inc.

Equities

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-23 pm EST			5-day change	1st Jan Change
277.88 ^USD	+1.62%		+3.32%	+6.61%

Jan. 17	Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	MT
Jan. 17	Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	MT

Highlights

Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	Jan. 17	MT
Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	Jan. 17	MT
Amgen Says Lumakras With Vectibix Approved by FDA for Metastatic Colorectal Cancer	Jan. 17	MT
Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	Jan. 17	MT
Amgen Inc. Announces FDA Approves LUMAKRAS® in Combination with Vectibix® (Panitumumab) for Chemorefractory KRAS G12C-Mutated Metastatic Colorectal Cancer	Jan. 17	CI
Wells Fargo Cuts Price Target on Amgen to $280 From $335, Maintains Equalweight Rating	Jan. 10	MT
Goldman Sachs Adjusts Price Target on Amgen to $370 From $375, Maintains Buy Rating	Jan. 08	MT
Asher Bio Announces Clinical Trial Collaboration and Supply Agreement with Amgen on Etakafusp Alfa in Combination with Bispecific T-cell Engager in Patients with Small Cell Lung Cancer	Jan. 08	CI
Truist Lowers Price Target on Amgen to $298 From $333, Keeps Hold Rating	Jan. 08	MT
RBC Trims Price Target on Amgen to $324 From $330, Keeps Outperform Rating	Jan. 07	MT
Amgen?s IMDYLLTRA Granted a Conditional Marketing Authorisation for Third-Line Treatment of Extensive-Stage Small Cell Lung Cancer in the United Kingdom	Jan. 06	CI
Amgen's Tarlatamab Approved by UK Regulator to Treat Lung Cancer	Dec. 31	MT
Eli Lilly, Amgen Sue HHS for Unlawful Certifications of Drug Discount Program Recipients	Dec. 23	MT
Lilly, Amgen Sue HHS Over Certification of Drug Discount Program Recipients	Dec. 23	MT
Top Midday Stories: Novo Nordisk Shares Drop After Obesity Treatment Falls Short of Expectations; CFPB Sues 3 Big Banks Over Alleged Zelle Fraud	Dec. 20	MT
Amgen, Eli Lilly, Viking Therapeutics Shares Rise Pre-Bell After Novo Nordisk's Obesity Treatment Falls Short of Expectations	Dec. 20	MT
Jefferies Adjusts Amgen Price Target to $350 From $380, Maintains Buy Rating	Dec. 19	MT
Merck Strikes Deal With China's Hansoh Pharma to Develop Weight Loss Drug	Dec. 18	MT
UBS Cuts Price Target on Amgen to $280 From $326, Maintains Neutral Rating	Dec. 17	MT
Amgen Boosts Quarterly Dividend by Nearly 6%	Dec. 10	DJ
Amgen Increases Quarterly Dividend to $2.38, Payable March 7 to Shareholders of Record Feb. 14	Dec. 10	MT
Amgen Inc. Declares Dividend for First Quarter of 2025, Payable on March 7, 2025	Dec. 10	CI
Amgen Inc. Announces Blincyto (Blinatumomab) Added to Chemotherapy Significantly Improves Survival in Newly Diagnosed Pediatric Patients with B-Cell Precursor Acute Lymphoblastic Leukemia (B-All)	Dec. 07	CI
Amgen Plans $1 Billion North Carolina Manufacturing Plant	Dec. 05	DJ
Amgen Expanding in North Carolina With $1 Billion New Manufacturing Site	Dec. 05	MT

Become a member to access more news.

100% Free Registration

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Amgen Inc.

Equities

AMGN

US0311621009

Pharmaceuticals

Highlights

Filters